SILENCE THERAPEUTICS PLC SPON ADS EACH REP 3 ORD SHS SLN 深 沪
等待开盘 09-17 09:30:00 美东时间
4.85
+0.120
+2.54%
华盛通- 最 高4.90
- 今 开4.74
- 成交量 6.74万股
- 最 低 4.65
- 昨 收 4.73
- 总市值 2.29亿
- 52周最高 20.48
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.97
- 委 比 48.45%
- 总股本 4723.39万
- 历史最高 35.00
- 量 比 0.88
- 振 幅 5.29%
- 历史最低 1.97
- 每 手 1
- 风险率 5.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
今天 10:15
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.
09-16 18:49
Michael Davidson Resigns from Silence Therapeutics Board
The latest announcement is out from Silence Therapeutics ( ($SLN) ). On August ...
08-14 18:57
Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $35 Price Target
Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $35 price target.
08-08 19:57
Silence Therapeutics Q2 EPS $(0.19) Beats $(0.23) Estimate, Sales $224.000K Miss $5.430M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 35.71 percent decrease over losses of $(0.14) per share
08-07 19:55
Silence Therapeutics Passes Key Resolutions at AGM
Silence Therapeutics ( ($SLN) ) just unveiled an announcement. On June 26, 2025...
06-27 19:29
美股大行评级 | 潜在涨幅290.69%！乌龙制药获丰业银行升目标价至47美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140565699993591809.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持乌龙制药(URGN)"跑赢大市"评级，目标价从23美元升至47美元</p> <p>• Guggenheim：维持ADC Therapeutics(ADCT)"买入"评级，目标价从7美元升至10美元</p>
06-16 08:40
Silence Therapeutics Presents Additional Data Showcasing SANRECO Phase 1 Study Of Divesiran In Patients With PV At EHA 2025 Annual Meeting
Updated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of DivesiranCompany Also Announces SANRECO Phase 2 Study Has Exceeded 50% Enrollment - On-track for
06-13 04:02
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers CNS Pharma (NASDAQ:CNSP) shares rose 90.1% to $2.3 during Tuesday's pr...
05-13 20:10
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
